NBIX News and Press, Neurocrine Biosciences Inc. From 11/01/21

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021 PR Newswire SAN DIEGO , Nov. 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorde...

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 1st, after market close. The consensus EPS Estimate is $0.81 (-16.5% Y/Y) and the consensus Revenue Estimate is $297.32M (+15.0% Y/Y). Canaccord Genuity lowered the recommendation on Neurocri...

Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting PR Newswire SAN DIEGO , Oct. 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results Conference Call and Webcast Scheduled for Monday, November 1 PR Newswire SAN DIEGO , Oct. 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: ...

Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic - The Sculpture "Monumental Moments™ - The Hug" Revealed at NYC's Lincoln Center o...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Evercore ISI has set up its list of key catalysts for the rest of 2021 in the biotechnology sector - including early-stage data readouts as well as some important legal and regulatory updates ahead for particular companies. Along the way it tees up its rule of thumb on biotech catalysts: "Alw...

Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) have been granted buy ratings at Needham as the firm initiated the coverage on companies focused on neurological diseases despite hurdles for therapeutic development in an area with a significant unmet need. For Biogen (BIIB), the analy...

Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021 - Long-term Data from KINECT 4 Study Found that Long-Term Tardive Dyskinesia (TD) Symptom Reductions were Achieved with Once-Daily INGREZZA ...

BURNABY, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regula...